|Bid||7.46 x 0|
|Ask||7.48 x 0|
|Day's Range||7.40 - 7.49|
|52 Week Range||7.10 - 8.88|
|Beta (5Y Monthly)||0.68|
|PE Ratio (TTM)||49.40|
|Earnings Date||Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.16|
PROBUPHINE® is also listed for reimbursement through the Non-Insured Health Benefit (NIHB) and Veteran Affairs Canada drug plansPROBUPHINE® is the first and only buprenorphine.
Knight expects to take over commercial activities from Debiopharm’s current partner Allergan and begin recording revenues in early 2020. Previously, Trelstar® was successfully launched and commercialized in Canada by Paladin Labs Inc. between 2006 to 2014.
Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company and Debiopharm, a Swiss-based, global biopharmaceutical company, today announced that they have entered into an exclusive agreement that grants Knight the rights to commercialize Trelstar® (triptorelin) in Canada. Knight expects to take over commercial activities from Debiopharm's current partner Allergan and begin recording revenues in early 2020. Previously, Trelstar® was successfully launched and commercialized in Canada by Paladin Labs Inc. between 2006 to 2014.
MONTREAL, Jan. 07, 2020 -- Knight Therapeutics Inc. (TSX: GUD) ("Knight") a leading pan-American (ex-USA) specialty pharmaceutical company, announced today that Samira Sakhia,.
Knight Therapeutics Inc. (GUD.TO) and its wholly owned subsidiary 1178991 CANADA INC. ("Knight" or “Offeror”) today announced that, further to its acquisition of a controlling interest (the “Transfer of Control”) in Biotoscana Investments S.A. (“GBT” or “Company”), it has submitted to B3 S.A. – Brasil, Bolsa, Balcão (“B3”) the authorization request to carry out a Unified Tender Offer (as defined below) for the acquisition of all outstanding Brazilian Depositary Receipts – BDRs of GBT (“BDRs”). The Unified Tender Offer aims at (i) fulfilling Knight’s statutory obligation to conduct a public offer for the acquisition of the outstanding BDRs following the Transfer of Control (“Tag Along Tender Offer”); and (ii) the voluntary discontinuity of the BDRs Program of the Company (“Discontinuity of the BDR Program”).
As announced on October 21, 2019, Knight paid BRL 10.96 per share or BRL 596 million (C$187 million(1)) (“Purchase Price”) in cash consideration for this controlling interest in GBT. Knight now controls the board of directors of GBT.
Knight Therapeutics Inc. (GUD.TO) (“Knight”) and TherapeuticsMD, Inc. (TXMD) (“TherapeuticsMD”) announced today that Knight's New Drug Submission (NDS) for Bijuva® has been accepted for review by Health Canada. Bijuva is a bio-identical* hormone therapy combination of estradiol and progesterone in a single, daily oral capsule intended for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with intact uteri.
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, today announced Health Canada approval of the TULSA-PRO® system for the ablation of low to intermediate risk organ-confined prostate cancer. TULSA-PRO® is a transurethral prostate tissue ablation system that combines real-time Magnetic Resonance Imaging (“MRI”) with robotically-driven directional thermal ultrasound and closed-loop temperature feedback control software to deliver predictable physician prescribed ablation of whole-gland or partial prostate tissue.
Knight and Medison have entered into a definitive agreement pursuant to which Knight will sell to the Medison group all of Knight’s shares in Medison, reflecting approximately 28.3% of the share capital of Medison, in consideration for CA$77,000,000 payable in cash. In addition, the parties agreed to release each other from all claims and withdraw all legal proceedings initiated by both parties.
MONTREAL, Nov. 12, 2019 -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a Canadian specialty pharmaceutical company, today reported financial results for its third quarter.
MONTREAL, Nov. 05, 2019 -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, will release its third quarter 2019 financial.
Knight Therapeutics Inc. (GUD.TO) (“Knight”) and TherapeuticsMD, Inc. (TXMD) (“TherapeuticsMD”) announced today that Knight's New Drug Submission (NDS) for Joyesta™ has been accepted for review by Health Canada. Joyesta, licensed from TherapeuticsMD, is an applicator-free estradiol softgel vaginal capsule for the treatment of postmenopausal symptoms of vulvar and vaginal atrophy due to estrogen deficiency. Joyesta is marketed as IMVEXXY® (estradiol vaginal inserts) by TherapeuticsMD in the U.S., for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.
Knight Therapeutics Inc. (GUD.TO) (“Knight”), a leading Canadian specialty pharmaceutical company, and SIFI S.p.A. (“SIFI”), a prominent Italian Eye Care company, today announced that Health Canada has approved NETILDEX® for the treatment of inflammatory ocular conditions of the anterior segment of the eye following cataract surgery where adjunct topical therapy to reduce the risk of bacterial infection is appropriate. Knight and SIFI entered into an exclusive Canadian agreement NETILDEX® in August 2016. “We are excited about the approval of NETILDEX® in Canada, providing patients with a new antibiotic with a well-established corticosteroid” said Jonathan Ross Goodman, Chief Executive Officer of Knight.
Knight Therapeutics will buy Brazilian pharmaceutical company Biotoscana Investments in a deal valued at 1.16 billion reais ($281 million) that will create a pharmaceutical platform in fast growing markets in Latin America. In a securities filing on Monday, Knight said it will acquire a 51% interest in Biotoscana for 596 million reais ($144 million) from controlling shareholders Advent International and Essex Woodlands. Knight will launch a mandatory tender offer to acquire the remaining 49% from public shareholders in similar terms.
Knight Therapeutics Inc. (GUD.TO) ("Knight") today announced that it has entered into a definitive agreement under which Knight will acquire a 51.21% interest in Biotoscana Investments S.A. (B3:GBIO33) (“GBT” or “Grupo Biotoscana”) from a controlling shareholder group that includes Advent International and Essex Woodlands, among others, for BRL 10.96 per share. This implies a 22.2% premium to GBT’s 30-day volume weighted average share price as of October 18, 2019.
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...